Search Results
Mindful Moms study
This study (Mindful Moms) is being done to understand how an 8-week app-based mindfulness program called Calm impacts breastfeeding and maternal well-being. Eligible participants will be asked to complete three online surveys (each survey will take about 20 minutes) and take part in an 8-week app-based mindfulness program. Eligible participants will also be asked to take part in one online interview that will take about 25-30 minutes once the mindfulness program is over.
Participants will take part in one of two groups: A group asked to take part in a free 8-week app-based mindfulness program on their smartphone starting when they are 36 weeks pregnant or 4 weeks after delivery. The program will teach participants about mindfulness and breathing strategies to assist with calming their mind and body. or A group asked to take part in a free 8-week app-based mindfulness program on your smartphone starting 4 weeks or 12 weeks after they deliver. The program will teach participants about mindfulness and breathing strategies to assist with calming their mind and body. Participants will also be asked to complete three online surveys (each survey will take about 20 minutes) and take part in one online interview that will take about 25-30 minutes once the mindfulness program is over.
$130
currently pregnant (12 to 34 weeks) or recently delivered (within the past 4 weeks)
intend to or are currently breastfeeding
daily access to a smartphone
willing to download a free mobile app
Phase II Trial of Palbociclib with Fulvestrant in Individuals with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer who have Progressed on Treatment with Palbociclib and an Aromatase Inhibitor
In this phase II trial, we will determine the progression-free survival (PFS) of the cyclin dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib with fulvestrant in women and men with estrogen or progesterone receptor (ER/PR) positive, HER2-negative metastatic breast cancer (MBC) who progressed on treatment with palbociclib and an aromatase inhibitor (AI). We will also determine the prevalence rate of estrogen eceptor α (ESR1) and phosphatidylinositol-3-kinase (PI3K) mutations in the study population.
Participants will be required to come to the clinic every three weeks for evaluation and fulvestrant injections, take medication correctly, keep all appointments.
Histologically or cytologically confirmed adenocarcinoma of the breast with evidence of metastatic disease (stage IV) or locally advanced disease,
ER-positive and/or PR-positive tumor (≥1% positive stained cells) • HER2-negative tumor
Progressed on and following at least 6 months of combined treatment with palbociclib and AI therapy for advanced/metastatic breast cancer, and be able and willing to receive additional palbociclib treatment
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Concurrent use of any of the following medications during study participation: • Inhibitors or inducers of CYP3A4 that may affect serum concentrations of palbociclib
Major surgery, chemotherapy, radiotherapy, or other anti-cancer therapy within 2 weeks before registration.
Any other malignancy within 3 years prior to registration, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
Prior hematopoietic stem cell or bone marrow transplantation.
SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
Microcystic lymphatic malformations (mLMs) are masses of spongy tissue that may have small fluid-filled cysts. They are made of abnormally large or misshapen lymph vessels that do not work correctly. They are usually present at birth and get worse over time. Complications of mLMs include infection, bleeding, leaking of lymphatic fluid, disfigurement, and impaired mobility. The purpose of this study is to find out if the study medicine, sirolimus 3.9% topical gel, can help with the treatment of mLMs.
Total duration of the study is approximately 14 months, with up to 8 visits (approximately 1 visit per month). 5 visits will occur in person and 3 visits will be phone call visits. You will also complete 2 interviews. After the first 14 months, you will have phone call visits every 84 days until either the study is discontinued, or you decide to no longer participate. Procedures involved in the study include: medical history collection, physical exams, skin assessments, patient interviews, photographs, blood draws (at 3 visits), urine tests, and questionnaires.
At least 3 years old
Willing to follow all study guidelines
History of HIV or other immunodeficiency
Depressive Symptomatology and Inflammation
The purpose of this research is to investigate the associations between depressive symptoms and inflammation. The researchers are studying how specific symptoms of depression (such as fatigue, sadness, impaired concentration, and loss of pleasure) are related to markers of inflammation, which is a key component of our immune system. Volunteers with depressive symptoms, as well as volunteers without depressive symptoms are needed for this research study. This study includes an online survey to determine eligibility and one in-lab visit. Participants who are eligible will be scheduled for one in-lab visit (2.5-3h for participants with depressive symptoms & 1-2h for participants without depressive symptoms), where they will be asked to answer surveys with questions related to depressive symptoms and complete a number of tasks (using an iPad and a touch screen phone) that measure thinking skills including attention, memory and reaction time. Participants will also undergo a single blood draw to assess inflammatory markers.
Participation will require one in person visit at the CRC that takes from 1 to 1.5 hours total where they will have their blood drawn, fill out surveys about their mood, and complete cognitive tests.
30
No history of depression
Free of chronic inflammatory or autoimmune disorders
If female, not pregnant or nursing
Taking non-steroidal anti-inflammatory agents or statins everyday within the past month
Taking antipsychotics or mood stabilizers
If female, are post-menopausal or pregnancy/lactation
PSCI 24-018 Phase 1, open label clinical trial to treat Stage IV cancer patients with multiple patient-specific mutated cell surface proteins with chimeric antibodies
This study will examine if giving patients their cells that have been modified in the lab will help control their cancer.
Subjects will be required to come to all visits. Each treatment will take 2-5 hours and there will be a total of 10 treatments over a 14 week period.
Subjects who have refractory or progressive disease after at least 1 line of systemic treatment
Subjects must have measurable disease
Known human immunodeficiency virus infection.
Subjects who have received any cytotoxic treatment within 3 weeks of antibody treatment.
Subjects who have received any radiotreatment to the primary sample site within the last 14 days
Pilot Study to Assess Medication Adherence, Health Literacy, and Technological Literacy among African Americans and Latinos with Hypertension
This pilot study aims explore the health literacy and medication adherence found among African Americans and Latinos with hypertension receiving care at Hamilton Health Center in Harrisburg PA. We also aim to determine the feasibility of the iPad or smartphone as a tool for accessing health related information among African American and Latino patients with hypertension receiving care at clinics at Hamilton Health Center in Harrisburg PA. The expected outcomes of this project are to obtain a better understand of the literacy levels and adherence behaviors of African Americans and Latinos in Harrisburg, Pennsylvania. The findings from this study will provide valuable insights into the health management behaviors of this community and determine if there is a need to develop a mobile health application for the management of hypertension.
Prescribed medication for high blood pressure
African American/Black (Hispanic or Non-Hispanic) or White (Hispanic)
21 years and older
Able to speak and read English
CO-CREATION OF DIGITAL TOOLKITS FOR ENHANCING THE RESILIENCE OF LOW-INCOME HOUSING IN SELECTED LOCATIONS IN FLORIDA AND PENNSYLVANIA
This study aims to assess engineering design solutions for sustainable, low-cost housing which can be able to withstand extreme heat and flooding disasters. The information will be used in digital toolkits and platforms to provide recommendations to residents in this area to learn the options they can use to make their housing resilient to extreme events and how they can access the information to guide them in the creation of resilient, sustainable and affordable houses in flood and extreme heat prone areas.
The study will interview the subject matter experts for a maximum of one hour to obtain their experiential input on engineering design recommendations in Flood and extreme heat-prone areas in Florida and Pennsylvania. The interview will be on zoom
All genders
Only Subject matter experts working with academic institution, Non-profit organizations and networks, government and private sectors, research centers and are in the field of housing, natural disasters, climate change adaptation and humanitarian response
Adults who are not subject matter experts of housing, natural disasters, climate change adaptation and humanitarian response
Any adult who qualifies for the inclusion criteria but does not wish to take part in the study
PARPAML: A Phase 1 Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy
The purpose of this study is to find out what effects, good and/or bad, study treatment with talazoparib in combination with the chemotherapy drugs topotecan and gemcitabine has on pediatric patients with acute myeloid leukemia (AML) that has returned or has not responded to treatment. The study drug talazoparib has been chosen because there is evidence that is can reduce tumor activity in a more specific way than chemotherapy.
If you join the study, you will given a certain dose of the study drug talazoparib, and of the chemotherapy drugs topotecan and gemcitabine. You may be asked to provide biological samples (such as blood or bone marrow) and undergo procedures that might be different from a regular medical examination. This study will involve screening, treatment, and follow up period. During screening, the study doctor will determine whether you are eligible for the study. If you are eligible and are enrolled into the study, you will have 2-3 months of active participation, including collection of information from you, admission to the hospital for a minimum of 5-7 days, and at least weekly visits to the study center.
BCC015: Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
This is a study of the drug DFMO (difluoromethylornithine) for neuroblastoma that has returned or not responded to treatment. DFMO is an oral drug that inhibits a certain enzyme (protein) in blood which is associated with a bad outcome in neuroblastoma cases. Cancer cells have pathways that drive the cancer to grow and DFMO targets the specific pathway of this enzyme to turn these cells off.
You will have exams, tests, and procedures while on the study to evaluate whether you can participate in the study and how you are doing while on the study. These include physical exams, blood tests, urine tests, bone marrow aspirate and biopsies, heart tests, hearing tests, and imaging evaluations such as CT scans and MIBG or PET scans. You will receive treatment on this study for a total of about 2 years. After treatment, you will have follow-up examinations and medical tests. We would like to continue to find out about your health for about 5 years after you complete the study.
Completed upfront therapy with at least 4 cycles of aggressive multi-drug chemotherapy
Currently receiving another investigational drug
Using grip force as a measure of fear in humans during a robot guided haunted house scenario
The objectives of the study are to determine whether grip force is related to participants’ fear and whether touch feedback from a robot can effectively communicate risk in a simulated high stress environment. We hypothesize that grip force increases in stressful situations like walking through a haunted house. Like in a real haunted house, people often find comfort in holding hands with someone as they walk through. In this study, a participant walks through a virtual haunted house.
There will be one in person visit. Participant will wear VR equipment and chest heart rate monitor. They will hold a virtual robot's hand and walk through a VR haunted house environment until it is over. They will then answer a brief survey.
15
Must not be suffering from anxiety disorders and/or panic attacks.
Must not be suffering from any known heart conditions.
Must not, to your knowledge, be prone to nausea when experiencing VR
Motion sickness caused by VR
Heart problems
Anxiety disorder
prone to nausea in VR
Investigating the effect of restaurant environment on food intake using mixed reality application.
This study investigates the influence of different rest design of restaurant on participants’ food consumption behavior. More specifically, visually pleasant versus visually unpleasant design elements are included in two cafe settings to study their influence on participant liking, and emotion response. To accomplish this, we will conduct an experiment where participants will be eating a meal while immersed in a virtual café interior with two different designs using a VR headset. Their food intake will be measured.
Participants will visit the lab for 3 sessions to eat a meal each time while wearing an immersive virtual reality headset.
$30 amazon gift card
Fluent in English
Free of self-reported food allergies
No diagnosis of cognitive or physical disabilities that may affect appetite or eating behaviors
No diagnosis of disabilities that may affect sensory proprioception related to virtual reality
Not fluent in English
Have self-reported food allergies
Have a diagnosis of cognitive or physical disabilities that may affect appetite or eating behaviors
Have a diagnosis of disabilities that may affect sensory proprioception related to virtual reality
PSCI 24-127 EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)
This study will be using a test called Oncodetect to identify specific gene mutations. These may help in predicting the risk of the cancer coming back.
Subjects will need to agree to come to the hospital for 14 visits to have blood drawn.
$375.00
ECOG performance status 0 or 1.
Histologically confirmed invasive carcinoma of the breast.
Planned neoadjuvant therapy which includes cytotoxic chemotherapy.
Tumor size ≥ 2.1 cm in greatest diameter.
Initiated neoadjuvant therapy for current breast cancer diagnosis.
diagnosis of another invasive cancer
Known pregnancy at time of enrollment.
BCC022: Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
The purpose of this research is to evaluate the investigational drug, tipifarnib (a pill taken by mouth), in combination with the FDA approved drug, naxitamab, administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins).
You will be asked to come in for screening and at the start of each cycle (every 28 days), and at the end of study treatment to have tests done (these may include a physical exam, blood tests, and electrocardiogram [ECG]). During the first cycle you will need to have blood tests done weekly. You will also need to come in during Days 1-5 of each cycle to receive the study treatment. You will also have scans and a bone marrow biopsy (tissue sample) and aspirate (fluid and cells) done at the start of study, every 2 cycles, and at the end of study.
Age >12 months of age at enrollment
Age 6 years or older for safety run in
Currently receiving another investigational drug
Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification for Higher Genomic Risk with Radiation (NRG-GU009) (PSCI# 20-141)
This study is being done to answer the following questions: If you have high risk prostate cancer, a low gene risk score and plan to receive radiation therapy, is a shorter hormone therapy treatment as effective at controlling your cancer compared to the usual 24 month hormone therapy treatment? If you have high risk prostate cancer, a high gene risk score and plan to receive radiation therapy, does adding two new hormone therapy drugs to the usual treatment increase the length of time without your prostate cancer spreading as compared to the usual treatment? We are doing this study because we want to find out if these approaches are better, similar, or worse than the usual approach for your type of prostate cancer. The usual treatment is defined as the care most people get for prostate cancer.
This study is being done to answer the following questions: If you have high risk prostate cancer, a low gene risk score and plan to receive radiation therapy, is a shorter hormone therapy treatment as effective at controlling your cancer compared to the usual 24 month hormone therapy treatment? If you have high risk prostate cancer, a high gene risk score and plan to receive radiation therapy, does adding two new hormone therapy drugs to the usual treatment increase the length of time without your prostate cancer spreading as compared to the usual treatment? We are doing this study because we want to find out if these approaches are better, similar, or worse than the usual approach for your type of prostate cancer. The usual treatment is defined as the care most people get for prostate cance
High-risk disease
ECOG Performance Status of 0-2 within 120 days prior to registration
Adequate hematologic function within 120 days prior to registration
Adequate hepatic function within 120 days prior to registration
Prior systemic chemotherapy within ≤3 years prior to registration
Current use of 5-alpha reductase inhibitor
Didanosine (DDI) antiretroviral therapy is not permitted
History of seizure disorder or current severe or unstable angina
Lexical and sentence processing in novice L2 learners: Psycholinguistic and neurocognitive investigations
We are studying how children and adults learn second languages in the classroom. To do this, we ask children and adults to read words or sentences in English and in Spanish while we record brainwaves using noninvasive sensors. The participant wears a cap that looks like a swimmers cap with the sensors attached to it.
Middle school students enrolled in first year Spanish
Monolingual English speaker
Right-handed
Normal or corrected-to-normal vision
History of neurological disorders
Uncorrected vision
The Blended4Blues Study
An intervention using an internet-based platform for coping and mood difficulties. Participants will be able to use cognitive-behavioral therapy (CBT) based online self-help modules over the course of a 10-week program.
Participants will engage with online materials on a weekly basis for 10 weeks.
$25
U.S. resident currently residing in the United States
Fluent in the English language in terms of speaking, listening, reading, and writing.
Aged 18-19 years
Presence of depressive symptoms as measured by a score ≥ 10 on the QIDS-17-SR
Unable to speak, read, listen, and write English fluently.
Do not meet inclusion criteria for clinical depression on the QIDS-17-SR, i.e., score ≥ 10
Does not fulfill DSM-5 Criteria for MDE on the MINI Clinical Interview.
Expressed suicidal ideation defined as score >1 on the suicide ideation item on the PHQ-9, and/or on the MINI.
PSCI 21-190 A randomized study of the efficacy of Daromun Neoadjuvant treatment followed by surgery
The purpose of this study is to test the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy)
Arm 1, 19 in person visits, blood drawn at each visit Arm 2, 14 in person visits, blood drawn at each visit
Eligible subjects must have measurable disease and must be candidate for intralesional therapy with at least one injectable cutaneous, subcutaneous, or nodal melanoma lesion
Males or females, age ≥ 18 years
ECOG Performance Status/WHO Performance Status ≤ 1.
Life expectancy of > 24 months
Evidence of distant metastases at screening
Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ
Presence of active infections
History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris
Using Apple Watches to Assess Substance Co-use in Young Adults (Project SPARC Pre-Pilot): a Feasibility Study
In this study, we aim to investigate the feasibility and usability of using Apple Watches to collect substance co-use data, as well as contextual data that could potentially be associated with substance co-use data (location, social context, mood, health, etc.)
Currently owns and uses an iPhone with iOS version 15 or newer
Currently owns and uses an Apple Watch with watchOS version 8 or newer
Determined eligible through screener
PSCI 23-020: EA8212 A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
If you decide to take part in this study, you will either get Gemcitabine and Docetaxel instilled through a catheter weekly in your bladder for up to 6 weeks, or you will get BCG instilled weekly in your bladder for up to 6 weeks. Your initial therapy may be followed with maintenance therapy.
If you decide to take part in this study, you will either get Gemcitabine and Docetaxel instilled through a catheter weekly in your bladder for up to 6 weeks, or you will get BCG instilled weekly in your bladder for up to 6 weeks. Your initial therapy may be followed with maintenance therapy. After you finish your treatment, your doctor will continue to follow your condition for 5 years with a combination of cystoscopies (inserting a telescope in your bladder) and CT scans (to take images of your body) in order to detect cancer recurrence.
Patient must have histologically confirmed high-grade non-muscle invasive urothelial carcinoma of the bladder (HgTa, HGT1, CIS, HgTa + CIS, or HGT1 + CIS stage)
Patient must have ECOG Performance Status 0-2.
Patient must have all visible papillary tumor resected by the treating urologist at the site registering the patient to this protocol prior to randomization.
Patient may have received prior systemic gemcitabine or docetaxel use if it was for a non-bladder malignancy
Patient must have not received prior intravesical therapy for bladder cancer, with the exception of perioperative chemotherapy at the time of TURBT.
Patient must not have pure squamous cell carcinoma or adenocarcinoma.
Patient must not have any component of neuroendocrine carcinoma (i.e., small cell or large cell).
Patient must not have any component of sarcomatoid, micropapillary, or plasmacytoid variant histology.
Early Identification in Older Adults of Risks to Sleep Health, Movement, and Cognition Using Ecological Methods
This proposal is a prospective study in which we will collect both subjective and objective quantitative data from older adults residing in independent living retirement communities, microlongitudinally (~1wk). Comprehensive measures of sleep health, cognition, and movement will be collected at community residences. The first phase of this project will recruit local, State College area adults over 70 residing in independent living facilities (e.g., Foxdale Village and The Village at Penn State). A second phase of data collection will extend to community-based older adults in rural parts of Centre and nearby counties. With this prospective, microlongitudinal information we will evaluate the characteristics of sleep predictive of daytime cognitive and neurobehavioral function and use those conclusions to inform nonpharmacologic, preventative interventions for older adults.
After consent, there will be 6 study visits at either Penn State University Park campus or at the participant's personal residence. Study participation lasts about 1 week. Participants wear non-invasive ambulatory watch-like activity monitors throughout (both day and night) the week. Participants complete electronic surveys and cognitive tests 6 times daily, with additional surveys at study conclusion. Sleep and daytime brain and heart activity are recorded (without video) using non-invasive clinical-type wire sensors applied to the face, head, and chest. Wires are worn on the face, head, and chest throughout the first two study nights. Wires are worn on the head and chest throughout the first two study days. There is not a sleep intervention in this study. We are collecting data about the typical sleep health of older adults and its relation to cognitive health.
$350
Resident of PA, Centre County region
Living without functional assistance
Able to walk unassisted for at least 5min
Evidence of cognitive impairment (will be tested)
A qualitative exploration of rurality, physical activity, and intervention preferences among older residents in Pennsylvania
This study will use interviews to explore to explore perceptions of rurality, physical activity behaviors and physical activity intervention preferences among rural older adults who live in Pennsylvania
Currently residing in Pennsylvania
Able to speak, read, and write in English
Not currently residing in Pennsylvania
Not able to speak, read, and write in English
ATHN 10: Rare Coagulation Disorders Project
This is a multi-center project in which the American Thrombosis & Hemostasis Network (ATHN) will offer free genotyping to individuals with Rare Coagulation Disorders (RCD).
One tube of blood will be collected during a routine clinic visit.
Must currently receive or have received care at and ATHN affiliated HTC
Subject must have opted into the ATHNdataset
The influence of estrogen on the thermoregulatory responses to heat stress in pre and postmenopausal women
The frequency and severity of heat waves has increased in the last decades. Women over 65 are at the most vulnerable to adverse events during these events. This sex difference only occurs in middle aged and older adults suggesting that menopause could play a role in increased risk in the heat for women. It is important to identify the role that the menopause transition plays in the ability to regulate body temperature in aging women. In this study, we will identify the role of estrogen levels in pre and post menopausal women on their ability to tolerate heat.
For this study, you will visit the lab for a screening visit, a maximal exercise test, and 6 experimental sessions. Before each experimental visit, you will swallow a temperature-sensing capsule 1-2 hours prior to arriving. In one type of experiment (passive heat stress), conducted during 2 visits, you will wear a suit with tubing running hot water to warm your body. A small catheter will be placed in your forearm to measure skin blood flow. In the other type of experiment (active heat stress), conducted during 4 visits, you will perform light exercise in heat and humidity on at least two separate days with different heat and humidity conditions. Participants will receive estrogen treatment for a portion of the study.
430
using hormonal contraceptives
History of Crohn's disease, diverticulitis, or other similar gastrointestinal disease
Medications that could alter cardiovascular responses or body temperature regulation during exercise (blood pressure reducers, fever reducers, anti-depressants, etc.)
Understanding experiences of international students with healthcare and antibiotics
This study examines the experiences of international students with regard to upper respiratory illnesses, healthcare, and use of antibiotics in their home countries and in the United States. The findings of the study will inform the development of training to improve healthcare providers’ communication skills for discussing antibiotics with international students.
Complete one online survey, which takes approximately 20 minutes.
10.00
College/university undergraduate or graduate student at a U.S. university
born and raised in and is currently a citizen of China, India, or South Korea
English speaking
lived in the United States for less than 7 years
Not a college or university student at a U.S. university
Not born or raised in and currently citizen of China, India, or South Korea
Not English speaking
Lived in the United States more than 7 years
Penn State SELF - Student Engagement, Learning and Flourishing
Substance misuse is a leading national problem, with young adults at high risk. We aim to develop a university resource that elucidates biobehavioral underpinnings of problematic student substance use at University Park campus. This initiative would inform services needed, provide engaged learning opportunities, connect with faculty, and catalyze high-impact, interdisciplinary research. In addition to this primary rationale, this study will allow us to capture detailed information about other critical student experiences such as food and housing insecurity, experiences of discrimination, and daily health practices to prevent the transmission of COVID-19. Participants will be asked to take a baseline survey followed by a 21- daily diary protocol (brief 5 minute survey each day for 21 days. For more information or to register interest in participating please see: https://projectself.psu.edu/register-your-interest/
Enrolled at UP
18-24 years old
Part-time students
Students located in the EEA
Older than 24
No graduate students
Understanding University Students' Daily Interaction with ChatGPT through the Lens of Self-Determination Theory
This study aims to learn about how university students interact with ChatGPT and how ChatGPT's support of autonomy, competence, and relatedness could either help or hinder students' ability to learn. We will interview students to understand how ChatGPT supports student learning and identify any challenges that may arise.
There will be a 60-minute interview.
$10
Use ChatGPT for their daily lives
Over 18 years old
Speak English
Students from non-EU countries
Under 18 years old
Do not use ChatGPT for their daily lives
Non-english speaker
Students from EU countries
Driver Training on the Advanced Driving Assistant System
This research aims to study the training knowledge that is essential for drivers to use Advanced Driving Assistant Systems safely and properly and identify the optimal training approaches.
If you participate in the first experiment, you will receive training of the in-vehicle system via videos and manuals, complete a driving task on the driving simulator, and answer questions from questionnaires. If you participate in the second experiment, there will be two visits. In the first visit, you will receive training via watching and interacting with online videos, watching an experimenter operating ADAS at the test track, or practicing the functions of ADAS in a vehicle at the test track. The functions in the training include adaptive cruise control, lane-keeping assistance, and Highway Driving Assist. In the second visit, you will complete a driving task on the driving simulator and answer questions from questionnaires.
$30 for experiment1 and $60 for experiment 2
Being fluent in English
Have a valid driver license for at least one year
have normal vision or corrected vision only wearing contact lenses
PSCI 23-002 CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2-Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
We are asking you to take part in this voluntary research study because you have ER+/HER2- early breast cancer with no evidence of disease following surgery. The purpose of this voluntary research study is to better understand the studied disease and associated health problems.
Participants will be required to come to all study visits, take the medication an instructed, let the study team know what medications you are taking, especially over the counter ones and to report any changes in how you are feeling.
Patient must be ≥18 years
histologically confirmed ER+/HER2- early-stage resected invasive breast cancer
a history of previous breast cancer
Chronic gastrointestinal disease
Major surgical procedure or significant traumatic injury within 2 weeks of randomisation
Defining the role of slow eye movements on limb motor control in younger and older adults
The purpose of this study is to define how eye movements contribute to eye-hand coordination in individuals of the age group 18-50 (young adults) and 65-80 (older adults). Specifically, the aim of the study is to understand how slow eye movements affect arm and hand movements. All procedures to be used in our study will be non-invasive. The task during the study will be performed with a robotic handle that participants will grasp with their right hand. They will interact with visual stimuli by moving the robotic handle. The robotic environment will attempt to simulate real-world mechanical interactions, such as those experienced during catching a ball.
During this study, we will ask you to come to our laboratory located in 23 Recreation Building, Pennsylvania State University, on two days separated by a maximum of 48 hours. Both sessions will last approximately 90-120 minutes. During the first session, we will review the procedures with you and if you agree to participate, you will sign this form and then proceed to perform the study. You will perform about 20-25 blocks of hand movements. Each block will consist of 24-30 trials and each trial will last between 3-5 seconds.The second day will be identical to the first day but the order of trials within a block will be changed.
$10/hour
Participants will be right-hand dominant individuals.
They will have normal or corrected-to-normal vision.
Participants should be able to sit upright in a chair for long periods (up to 2 and a half hours) with rest.
Participants should be able to grasp and move objects with both hands.
Any history of musculoskeletal disorders
Eye or vision problems (e.g., cataracts, glaucoma, a detached retina or macular degeneration).
Cognitive impairment
Medication that could make the participant drowsy or tired during the experiment.
Identifying views of Military Veterans Regarding Contemporary War and Conflict Reporting
This study will involve surveying and interviewing US military veterans and non-veterans regarding their perceptions of the quality, accuracy, and themes of contemporary war and conflict reporting.
Military Veteran
Current Member of the Military
Non-Military Civilians